D.C. Circuit Rules That FTC Can Change HSR Rules Targeted at Pharma Patents
In 2013, a FTC rulemaking deemed that the transfers of pharmaceutical patent rights to be reportable assets under the Hart-Scott-Rodino Act (“HSR”).
In 2013, a FTC rulemaking deemed that the transfers of pharmaceutical patent rights to be reportable assets under the Hart-Scott-Rodino Act (“HSR”).